ORIGINAL RESEARCH published: 17 June 2020 doi: 10.3389/fimmu.2020.01256 Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis 1 2 1 1 3 Edited by: Henrique Lemos , Eslam Mohamed , Rong Ou , Caroline McCardle , Xiaozhong Zheng , 3 4 3 1 Kutty Selva Nandakumar, Kris McGuire , Natalie Z. M. Homer , Damian J. Mole , Lei Huang * and 1 Southern Medical University, China Andrew L. Mellor * Reviewed by: 1 Immune Metabolism Laboratory, Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle Ursula Grohmann, University, Newcastle upon Tyne, United Kingdom, 2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, University of Perugia, Italy United States, 3 Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom, 4 Mass Sergio Rutella, Spectrometry Core, Edinburgh Clinical Research Facility, Centre for Cardiovascular Sciences, Queen’s Medical Research Nottingham Trent University, Institute, Edinburgh, United Kingdom United Kingdom Gilles J. Guillemin, Macquarie University, Australia Reinforcing defective tolerogenic processes slows progression of autoimmune (AI) *Correspondence: diseases and has potential to promote drug-free disease remission. Previously, Lei Huang we reported that DNA nanoparticles (DNPs) and cyclic dinucleotides (CDNs) slow
[email protected] Andrew L. Mellor progression of experimental autoimmune encephalomyelitis (EAE), a mouse model of
[email protected]